Literature DB >> 11796581

Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization.

David Kobiler1, Yehoshua Gozes, Hagai Rosenberg, Dino Marcus, Shaul Reuveny, Zeev Altboum.   

Abstract

The efficacy of passive immunization as a postexposure prophylactic measure for treatment of guinea pigs intranasally infected with Bacillus anthracis spores was evaluated. Antisera directed either against the lethal toxin components (PA or LF) or against a toxinogenic strain (Sterne) were used for this evaluation. All antisera exhibited high enzyme-linked immunosorbent assay titers against the corresponding antigens, high titers of neutralization of cytotoxicity activity in an in vitro mouse macrophages cell line (J774A.1), as well as in vivo neutralization of toxicity when administered either directly to Fisher rats prior to challenge with the lethal toxin or after incubation with the lethal toxin. In these tests, anti-LF antiserum exhibited the highest neutralization efficiency, followed by anti-Sterne and anti-PA. The time dependence and antibody dose necessary for conferring postexposure protection by the various antibodies of guinea pigs infected with 25 50% lethal doses of Vollum spores was examined. Rabbit anti-PA serum was found to be the most effective. Intraperitoneal injections of anti-PA serum given 24 h postinfection protected 90% of the infected animals, whereas anti-Sterne and anti-LF were less effective. These results further emphasizes the importance of anti-PA antibodies in conferring protection against B. anthracis infection and demonstrated the ability of such antibodies to be effectively applied as an efficient postexposure treatment against anthrax disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796581      PMCID: PMC127686          DOI: 10.1128/IAI.70.2.544-550.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures.

Authors:  M PUZISS; L C MANNING; J W LYNCH; I ABELOW; G G WRIGHT
Journal:  Appl Microbiol       Date:  1963-07

2.  Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production.

Authors:  F C BELTON; R E STRANGE
Journal:  Br J Exp Pathol       Date:  1954-04

Review 3.  Anthrax vaccine development: a continuing story.

Authors:  P Hambleton; P C Turnbull
Journal:  Adv Biotechnol Processes       Date:  1990

Review 4.  Treatment of anthrax in man: history and current concepts.

Authors:  G B Knudson
Journal:  Mil Med       Date:  1986-02       Impact factor: 1.437

5.  Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Authors:  S F Little; B E Ivins; P F Fellows; A M Friedlander
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

7.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

8.  Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.

Authors:  A M Friedlander
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

9.  Studies on an anthrax vaccine prepared from nonencapsulated variants of Bacillus anthracis.

Authors:  G PERSONEUS; M S COOPER; R C PERCIVAL
Journal:  Am J Vet Res       Date:  1956-01       Impact factor: 1.156

10.  Elaboration of Bacillus anthracis antigens in a new, defined culture medium.

Authors:  J D Ristroph; B E Ivins
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

View more
  43 in total

1.  An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.

Authors:  Nam-Kyu Lim; Jung-Hwan Kim; Mee Sook Oh; Sangyoon Lee; Se-Yeon Kim; Keun-Soo Kim; Hyun-Jung Kang; Hyo Jeong Hong; Kyung-Soo Inn
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.

Authors:  Phillip R Pittman; Susan F Leitman; Julio G Barrera Oro; Sarah L Norris; Nina M Marano; Manmohan V Ranadive; Bonnie S Sink; Kelly T McKee
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

3.  Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.

Authors:  Orit Gat; Haim Grosfeld; Naomi Ariel; Itzhak Inbar; Galia Zaide; Yehoshua Broder; Anat Zvi; Theodor Chitlaru; Zeev Altboum; Dana Stein; Sara Cohen; Avigdor Shafferman
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 4.  Genetic medicine strategies to protect against bioterrorism.

Authors:  Julie L Boyer; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

5.  Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits.

Authors:  Shay Weiss; David Kobiler; Haim Levy; Hadar Marcus; Avi Pass; Nili Rothschild; Zeev Altboum
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Anthrax toxin protective antigen: inhibition of channel function by chloroquine and related compounds and study of binding kinetics using the current noise analysis.

Authors:  Frank Orlik; Bettina Schiffler; Roland Benz
Journal:  Biophys J       Date:  2004-12-13       Impact factor: 4.033

Review 7.  Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines.

Authors:  Andrew J Phipps; Christopher Premanandan; Roy E Barnewall; Michael D Lairmore
Journal:  Microbiol Mol Biol Rev       Date:  2004-12       Impact factor: 11.056

8.  A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Authors:  Conrad P Quinn; Carol L Sabourin; Nancy A Niemuth; Han Li; Vera A Semenova; Thomas L Rudge; Heather J Mayfield; Jarad Schiffer; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; April M Brys; Robert E Hunt; Denyse Levesque; James E Estep; Roy E Barnewall; David M Robinson; Brian D Plikaytis; Nina Marano
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

9.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

10.  Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection.

Authors:  Ronit Rosenfeld; Hadar Marcus; Einat Ben-Arie; Bat-El Lachmi; Adva Mechaly; Shaul Reuveny; Orit Gat; Ohad Mazor; Arie Ordentlich
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.